Dr. Corey D. Clay, MD, PhD

Dr. Clay practices at Allergy Partners of New Mexico in Santa Fe, New Mexico.

Dr. Clay's NPI, 1417247727, was assigned on April 8, 2011. Dr. Clay graduated from Ohio State College of Medicine in 2011. Dr. Clay holds New Mexico license MD2019-0525.

Dr. Clay's primary practice is Allergy Partners of New Mexico, at 1651 Galisteo St, Santa Fe, NM 87505 in Santa Fe County. The practice phone is (505) 820-9870.

Dr. Clay's primary practice is Allergy Partners of New Mexico in Santa Fe, New Mexico. Dr. Clay is also affiliated with CHRISTUS St. Vincent Regional Medical Center. The medical group on file is Allergy Partners of Crestview Hills. Dmand AI also links Dr. Clay to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Clay practices, 2 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Clay's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Clay is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Clay's licenses on file in 3 states: New Mexico, Kentucky and Ohio.

Dmand AI lists asthma, chronic nasal allergies, chronic sinusitis, hives and immune deficiency disease among the conditions Dr. Clay treats.

CMS data shows 12,165 Medicare services from Dr. Clay across 19 procedure codes in 2024, for 506 Medicare patients. Medicare paid $183,965 for them. Every service was in an office.

CMS counts 506 Medicare patients who saw Dr. Clay in 2024. The largest group is 65 to 74, with 299 patients. 75% of them have high cholesterol, and 55% have arthritis. 6% are also on Medicaid. Their average risk score is 0.81, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Clay's median patient age at 54, with 62% women.

In 2024, Dr. Clay wrote 1,490 Medicare Part D claims for 323 patients. 67% of them were for generic drugs. CMS names the drug for 1,328 of them, across 32 drugs with 11 or more claims each, at $530,689 in total drug cost. In 2023, CMS named 1,251 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Clay for performance year 2024, reported as part of a group. Dr. Clay accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Clay, published from 2008 to 2016. 2009 was the busiest year, with 2. The most frequent topics are Francisella tularensis, Cells, Cultured and Macrophages. Dr. Clay has published most often in J Immunol. Dr. Clay's most frequent co-author is Larry S. Schlesinger, MD.

CMS Open Payments shows 661 general payments to Dr. Clay from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. AstraZeneca Pharmaceuticals LP paid the most, $3,427.

Dr. Clay graduated from Ohio State College of Medicine in 2011.

Dr. Clay is in network with 11 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.